王红胜

中山大学药学院教授、博导、副院长、教育部青年长江学者、国家重点研发计划青年首席科学家。

目前主要研究RNA修饰在肿瘤中的作用及其靶向治疗策略。先后获中山大学药学学士学位及香港浸会大学博士学位。

作为项目负责人先后主持国家重点研发计划青年项目、广东省自然基金卓越青年团队项目、国家自然科学基金(7项)、广东省杰出青年基金等10多项课题,累计竞争性纵向经费逾2000万元。

获中国抗癌协会青年科学家奖(2023)、中国药理学会施维雅青年药理学家奖(2019)、中国药学会以岭生物医药奖青年奖(2019)、中国药理学会青年药理学家奖(2018)、中国药学会赛诺菲青年生物药物奖(2016)、广东省自然科学基金杰出青年基金(2014)。

近年以通讯及第一作者在Natl Sci Rev、PNAS、Nat Commun、Nucleic Acid Res、Angew Chem等SCI期刊发表论文70余篇。通讯及第一作者论文总计影响因子超过700,其中30篇IF>10,3篇文章入选ESI高被引论文。总计引用次数超过7000次,h-index为50,入选全球顶尖前10万科学家,全球前2%顶尖科学家榜单。
Professor, Doctoral Supervisor, Vice Dean of the School of Pharmaceutical Sciences at Sun Yat-sen University, Young Yangtze River Scholar of the Ministry of Education, and Young Chief Scientist of the National Key Research and Development Program. Currently, his research focuses on the role of RNA modifications in tumors and their targeted therapeutic strategies. He holds a Bachelor's degree in Pharmacy from Sun Yat-sen University and a Ph.D. from Hong Kong Baptist University. 
 
As a project leader, he has presided over more than 10 research projects, including the Young Scientists Program of the National Key Research and Development Program, the Outstanding Youth Team Project of the Guangdong Natural Science Foundation, the National Natural Science Foundation of China (7 projects), and the Guangdong Outstanding Youth Fund, with a total competitive funding exceeding 20 million RMB.  
Awards and Honors:
- Young Scientist Award from the Chinese Anti-Cancer Association (2023);  
- Servier Young Pharmacologist Award from the Chinese Pharmacological Society (2019);  
- Yiling Biopharmaceutical Youth Award from the Chinese Pharmaceutical Association (2019);  
- Young Pharmacologist Award from the Chinese Pharmacological Society (2018);  
- Sanofi Young Biopharmaceutical Award from the Chinese Pharmaceutical Association (2016);  
- Outstanding Youth Fund of the Guangdong Natural Science Foundation (2014).  
Research Achievements:
In recent years, he has published over 70 SCI papers as a corresponding or first author in journals such as "National Science Review", "PNAS", "Nature Communications", "Nucleic Acids Research", and "Angewandte Chemie". The total impact factor of his corresponding and first-author papers exceeds 700, with 30 papers having an impact factor greater than 10. Three of his articles have been listed as ESI Highly Cited Papers. His work has been cited more than 7,000 times, with an h-index of 50. He has been recognized as one of the Top 100,000 Scientists Worldwide and included in the list of the Top 2% of Scientists Globally.
出版者信息








《广州医药》公众号